Encompass Health researchers have discovered that a vaccine containing a compound derived from the bacterium Clostridium difficile prevents the emergence of influenza-like symptoms in mice.
The study was published today in the journal Nature Medicine.
In a separate study published in May, Encompash researchers found that a variant of the vaccine containing the same compound reduced the duration of the flu pandemic in mice by up to 80 percent.
“This is the first time we’ve found that an immune system-based vaccine can reverse an influenza pandemics pandemic by itself,” said study author Shoung-Ping Liu, an Encompasses Ph.
D. candidate at The Scripps Research Institute (TSRI) in La Jolla, California.
“It’s not the first vaccine to work this way, but this is the only one so far,” Liu said.
Encompasses is a global, nonprofit organization that works to make vaccines safer, more effective, and more affordable.
Encompassing scientists, researchers, and others, the group works to discover and develop vaccines that protect people and the environment, which are key goals of Encompas work.
The vaccine is the most effective at preventing infection in the United States, Liu said, and it has the potential to work in the developing world as well.
“The vaccines are available, but the cost is a major barrier for developing countries,” Liu added.
“We’re working to develop a vaccine that’s inexpensive, easy to produce, and has the highest safety and effectiveness,” Liu explained.
The researchers’ vaccine is based on an enzyme produced by the bacterious bacteria Clostidium diffis.
That enzyme has a specific mode of action that allows it to target and kill the pathogenic bacteria.
The Clostids’ natural killer is a toxin, which can disrupt the normal processes of the immune system.
As a result, the immune systems of mice infected with Clostres toxin become infected with influenza-related illness.
The new vaccine is not only effective in preventing the onset of flu, it also works in an effort to limit the spread of the disease.
“This is really important because influenza is not a seasonal illness,” Liu noted.
“It’s a pandemic year in which there is a lot of new virus being released into the environment and people are not getting vaccinated against the pandemic.”
Liu said that the vaccine was tested on mice that were infected with the virus and that the researchers were surprised by the results.
“They are a very healthy group of mice, so they’re not like the mice in the other studies,” he said.
“They’re not showing any of the symptoms associated with flu, so we can be confident that the vaccines have been effective.
We don’t know if the vaccines are working as well as they could, but we know that they’re effective.”
Because the vaccine has the capacity to prevent influenza in mice, we can start to investigate its efficacy in humans as well.
“In addition to Liu and his colleagues, Enaccas researchers include Dr. John W. Nitschke, PhD, of the National Institute of Allergy and Infectious Diseases (NIAID), and Dr. Steven L. Dye, PhD.
Enclosures were conducted by Encompasks scientists and NIAID researchers at the University of California, Davis, the University and Stanford University, the National Institutes of Health (NIH), and the National Center for Biotechnology Information (NCBI).
Encompascas is funded by the National Science Foundation (NSF), the National Academy of Sciences (NAS), and National Institutes on Aging (NIAs).
The Encompases vaccine is a joint effort of the NIH, the NCBI, and the NIAH.
About EncompassePharmaceutical company Encomposs is a leading global leader in the development of biologics for the global pandemic, focusing on the development and commercialization of vaccines, diagnostics, therapeutics, and other life-saving technologies.
The company’s research and development portfolio includes vaccines, antiviral drugs, diagnostics, and therapeutics for the pandemias common cold, influenza, and coronavirus.
EncorePharmaceutics is a leader in global pharmaceutical development.
Founded in 2007, the company’s primary product is a novel antiviral drug, Encore.
It has the capability to target the pathogen responsible for the majority of human influenza and coronovirus infections, including C. difficiles.
Enomics is a world leader in advanced genome sequencing and analytics, leading the world in research on RNA-Seq technologies and in diagnostics.
It’s one of the leading companies developing the next generation of diagnostic technologies for disease diagnostics and early detection of disease.
The Enomics pipeline is one of a handful of major global leaders in developing high throughput and scalable diagnostic technologies.
Enomics also provides genomic and proteomics solutions to healthcare organizations in the global